Advancements in scientific methods have led to more humane alternatives to the rabbit pyrogen test (RPT), such as the in vitro monocyte-activation test (MAT). To address the transition from RPT to MAT, an international conference titled "The future of pyrogenicity testing: phasing out the rabbit pyrogen test" was organized by the European Directorate for the Quality of Medicines & HealthCare, the Council of Europe, and the European Partnership for Alternative Approaches to Animal Testing. The conference aimed to eliminate RPT from guidelines by 2026, promote MAT adoption, and identify challenges in discontinuing RPT. Participants, including stakeholders worldwide, emphasized the need for ongoing collaboration and international harmonization of regulatory requirements to facilitate MAT acceptance beyond Europe. Despite challenges, there was a unanimous commitment among participants to eliminate the unnecessary use of RPT in favor of more modern and humane testing methods.